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Type 2 diabetes mellitus (T2DM) is a risk factor for the development of Alzheimer’s disease, and changes in brain energy
metabolism have been suggested as a causative mechanism. The aim of this study was to investigate the cerebral metabolism of
the important amino acids glutamate and glutamine in the db/db mouse model of T2DM. Glutamate and glutamine are both
substrates for mitochondrial oxidation, and oxygen consumption was assessed in isolated brain mitochondria by Seahorse
XFe96 analysis. In addition, acutely isolated cerebral cortical and hippocampal slices were incubated with [U-13C]glutamate and
[U-13C]glutamine, and tissue extracts were analyzed by gas chromatography-mass spectrometry. The oxygen consumption rate
using glutamate and glutamine as substrates was not diﬀerent in isolated cerebral mitochondria of db/db mice compared to
controls. Hippocampal slices of db/db mice exhibited signiﬁcantly reduced 13C labeling in glutamate, glutamine, GABA, citrate,
and aspartate from metabolism of [U-13C]glutamate. Additionally, reduced 13C labeling were observed in GABA, citrate, and
aspartate from [U-13C]glutamine metabolism in hippocampal slices of db/db mice when compared to controls. None of these
changes were observed in cerebral cortical slices. The results suggest speciﬁc hippocampal impairments in glutamate and
glutamine metabolism, without aﬀecting mitochondrial oxidation of these substrates, in the db/db mouse.
1. Introduction
Type 2 diabetes mellitus (T2DM) is a multifaceted metabolic
disease characterized by an augmented level of blood glucose
caused by insulin resistance. T2DM has reached pandemic
proportions as over 400 million people are aﬀected by diabe-
tes [1]. T2DM is a major risk factor for the development of
Alzheimer’s disease (AD), and the hippocampus seems to
be particularly vulnerable in T2DM [2–4]. Insulin resistance
has been associated with reductions in cerebral glucose utili-
zation, a clinical hallmark of AD [5, 6]. This observation sug-
gests that altered brain energy metabolism might be an
accelerating factor in the development of AD in T2DM.
Glutamate is the main excitatory neurotransmitter in the
mammalian brain. Timely clearance and handling of gluta-
mate is essential fornormal cerebral function [7].Themajority
of released neurotransmitter glutamate is removed from the
synapse by adjacent astrocytes. In the astrocyte, glutamate
can be converted into glutamine by the astrocyte-speciﬁc
enzyme glutamine synthetase (GS). Glutamine can subse-
quently be transported to the neurons and converted back into
glutamate by the enzyme phosphate-activated glutaminase
(PAG),mainly expressed in the neurons. The exchange of glu-
tamate and glutamine between neurons and astrocytes is
termed the glutamate/glutamine cycle [7, 8]. Glutamate and
glutamine are also linked to cellular energy homeostasis.
Glutamate can be converted into α-ketoglutarate by
activity of glutamate dehydrogenase (GDH) or aspartate
aminotransferase (AAT) and thus be oxidized in the tri-
carboxylic acid (TCA) cycle [9–11]. Glutamine must be
converted into glutamate prior to oxidation. Both neurons
and astrocytes are able to metabolize glutamate and
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glutamine [12–14]. It has recently been shown that oxida-
tion of glutamate through GDH is important for cerebral
energy homeostasis [15].
Previously, we have shown that the common T2DM
mouse model, the db/db mouse, exhibits reduced glucose uti-
lization in both the cerebral cortex and hippocampus [16]. In
addition to this, isolated cerebral mitochondria consumed
more oxygen when given pyruvate and malate as substrates.
Here, we sought to investigate if cerebral glutamate and
glutamine metabolism is altered in the db/db mouse. To
assess this, oxygen consumption, that is, respiration, of
isolated whole-brain mitochondria was determined by
Seahorse XFe96 analysis, providing glutamate and glutamine
as primary substrates. Furthermore, acutely isolated cerebral
cortical and hippocampal slices of control and db/db mice
were incubated in media containing 13C-labeled glutamate
or glutamine and tissue extracts were subsequently analyzed
by gas chromatography-mass spectrometry (GC-MS) to
determine 13C enrichment and map the metabolism. Finally,
the expression of enzymes important for glutamate/glutamine
homeostasis was assessed by Western blotting.
2. Methods
2.1. Materials. The stable isotopes [U-13C]glutamate and
[U-13C]glutamine (both L isoform and 99% purity) were pur-
chased from Cambridge Isotope Laboratories (Tewksbury,
MA, USA). The following antibodies were purchased from
Abcam (Cambridge, United Kingdom): glutamate dehydroge-
nase (GDH, rabbit: ab34786), aspartate aminotransferase
(AAT, mouse: ab93928), glutamate decarboxylase 65 and 67
(GAD65 and 67, both mouse: ab26113 and ab26116),
phosphate-activated glutaminase (PAG, rabbit: ab93434),
and glutamine synthetase (GS, rabbit: ab73593). All other
chemicals used were of the purest grade available from regular
commercial sources.
2.2. Animals. Diabetic and obese homozygote db/db and
control mice (blood glucose: 25.6± 1.3mmol/L versus 11.1
± 0.4mmol/L, body weight: 51.6± 0.8 g versus 28.2± 0.9 g)
were obtained through mating of heterozygote (db/−) mice
at the Department of Drug Design and Pharmacology, Uni-
versity of Copenhagen. The breeding pairs were obtained
from Jackson Laboratories (Bar Harbor, ME, USA) on a
C57BL/6J background. All animals were kept in a
humidity-controlled facility with 12/12h light/dark cycle
and free access to water and chow. Animals were used at
15-16 weeks of age and grouped according to obese pheno-
type, meaning both lean wild-type and heterozygote oﬀspring
were used as controls as they cannot be phenotypically
distinguished [17, 18]. Both male and female mice were
included in this study. Blood glucose levels were assessed
using a BAYER Breeze 2 instrument. The experiments were
approved by the Danish National Ethics Committee and
were performed in agreement with the European Conven-
tion (ETS 123 of 1986).
2.3. Mitochondrial Isolation and Seahorse XFe96 Analysis.
Whole-brain mitochondria of control and db/db mice were
isolated in tandem as described previously [16]. Brieﬂy, ani-
mals were euthanized by cervical dislocation, the brain
quickly removed and placed in cold isolation buﬀer contain-
ing the following in mM: mannitol 210, sucrose 70, HEPES 5,
EGTA 1 and 0.5% BSA (fatty acid free), pH7.2, and homog-
enized using a Teﬂon douncer (750 revolutions/min, 7-8
strokes). The mitochondria in the homogenate were isolated
using a 21% Percoll gradient, and protein amounts were
determined by the Bradford method. The oxygen consump-
tion rate (OCR) of the isolated cerebral mitochondria was
assessed at 37°C using a Seahorse XFe96 analyzer (Seahorse
Biosciences, MA, USA). The isolated mitochondria were
suspended in assay buﬀer containing the following in mM:
mannitol 220, sucrose 70, KH2PO4 10, MgCl2 5, HEPES 2,
and 0.2% BSA (fatty acid free), pH=7.2. An aliquot of
25μL mitochondrial suspension, containing 4μg of protein,
was seated in each well and the plate was centrifuged
(2.000g× 20min at 4°C). The mitochondria were provided
with 37°C assay buﬀer containing 10mM glutamate or
10mM glutamine both in the presence of 10mM malate (all
ﬁnal concentrations) and analyzed immediately. Malate was
provided to support the pool of TCA cycle intermediates.
The sequence of analysis consisted ﬁrstly of a waiting period
of 10min, followed by two cycles of mixing (1min) and
waiting (3min). Subsequently, three cycles of mixing
(2min), waiting (1min), and measurements (3min) were
applied to establish the baseline OCR. During the subsequent
course of measurements, four compounds were injected, in the
following order: ADP (4mM), oligomycin A (2.5μg/mL),
carbonyl cyanide-p-triﬂuoromethoxyphenylhydrazone (FCCP,
8μM), and antimycin A (8μM)—all ﬁnal concentrations.
OCRs were calculated using the Wave software (Seahorse
Biosciences). Relative OCR levels were calculated by setting
the OCR at the third baseline measurement to 100%.
2.4. Preparation and Incubation of Acute Brain Slices.Acutely
isolated brain slices were prepared as previously described
[19, 20]. Brieﬂy, animals were euthanized by cervical
dislocation and the brain excised into ice-cold artiﬁcial
cerebrospinal ﬂuid (ACSF) containing the following in
mM: NaCl 128, NaHCO3 25, KCl 3, CaCl2 2, MgSO4
1.2, and KH2PO4 0.4, pH=7.4. The cerebral cortices and
hippocampi were sliced using a McIlwain Tissue Chopper
(The Vibratome Company, O’Fallon, MO, USA) into
350μm thick slices. The slices were incubated in 10mL
ACSF containing 10mM D-glucose for 60min to recover
from the slicing. Subsequently, the media were exchanged
for ACSF containing 0.5mM [U-13C]glutamate or 1mM
[U-13C]glutamine both in combination with 5mM D-glu-
cose, and the slices were incubated for 60min. The
incubations were terminated by transferring slices to ice-
cold 70% ethanol. Slice were sonicated and centrifuged
(20.000g× 20min) and the supernatant was lyophilized
and stored for later analysis. The pellets were saved for
protein determination by the Pierce method. The dry
brain slice extracts were reconstituted in H2O for deter-
mination of 13C enrichment and amino acid amounts
by GC-MS and HPLC analysis, respectively.
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2.5. Metabolic Mapping by Gas Chromatography-Mass
Spectrometry (GC-MS) Analysis. GC-MS analysis of 13C
enrichment in amino acids and metabolites from brain slice
extracts was performed as described by Walls et al. [21].
The natural abundance of 13C was taken into account using
data obtained from analysis of standards containing unla-
beled metabolites of interest. Data are presented as the %
13C enrichment of M + X, where M is the molecular ion of
the given metabolite and X is the number of 13C carbon
atoms in the molecule. The expected pattern of 13C labeling
from incubations with [U-13C]glutamate and [U-13C]gluta-
mine is given in Figure 1.
2.6. Amino Acid and Lactate Determination. Determination
of quantitative amounts of amino acids from brain slice
extracts was assessed by reversed-phase high-performance
liquid chromatography (HPLC) using precolumn o-
phthalaldehydederivatization andﬂuorescentdetection (exci-
tation λ = 338 nm, emission λ = 390 nm) as previously
described [19]. The amounts of lactate released from the
brain slices to the incubation medium were assessed using
an enzymatic kit, based on the coupled reactions between
lactate dehydrogenase and alanine aminotransferase, from
Boehringer Mannheim/R-Biopharm AG (Darmstadt,
Germany) according to the manufacturer’s instructions.
2.7. Western Blots. Cerebral cortical and hippocampal
homogenates of db/db and control mice were analyzed by
Western blotting using primary antibodies against GDH,
AAT, glutamate decarboxylase (GAD), PAG, and GS. Equal
amounts (30μg) of protein were separated by SDS-PAGE
using NuPAGE 4–12% Bis-Tris gels (Thermo Fisher Scien-
tiﬁc) before transferring the proteins to PVDF membranes.
The membranes were stained with Ponceau S solution for
validation of equal protein amounts, washed, and incubated
in the given primary antibodies, and appropriate HRP-
conjugated secondary antibodies (Dako) were used. The blots
were subsequently analyzed with ECL™ Prime Western Blot-
ting Detection Reagent and quantiﬁed using ImageJ software.
2.8. Data Presentation and Statistical Analysis. All data are
presented as means± standard error of the mean (SEM).
To test if diﬀerences between the control and db/db
groups were statistically signiﬁcant, Student’s t-test were
employed. P values of <0.05 were considered to be signif-
icant and are indicated with a single asterisk.
3. Results
3.1. Mitochondrial Oxidation of Glutamate and Glutamine.
To investigate if the cerebral mitochondrial oxidation of
glutamate and glutamine was altered in the db/db mice, oxy-
gen consumption rates (OCRs) of isolated whole-brain mito-
chondria were assessed with glutamate and glutamine as
substrates, both in the presence of malate. Glutamine is taken
up by the mitochondria and transformed into glutamate,
which can be converted into α-ketoglutarate and support
oxidative metabolism in the TCA cycle. Absolute and relative
OCRs of isolated whole-brain mitochondria from control
and db/db mice are presented in Figure 2. Addition of ADP
stimulates coupled respiration, which can be blocked by the
ATP synthase inhibitor oligomycin A. FCCP induces max-
imal uncoupled respiration, whereas antimycin A inhibits
complex III of the respiratory chain halting the ﬂow of
electrons. No signiﬁcant changes were observed in the
OCR of mitochondria from control and db/db mice when
provided with glutamate (Figure 2(a)) or glutamine
(Figure 2(b)) as respiratory substrates in the presence of
any of the four compounds. A tendency towards an overall
higher OCR was observed in the mitochondria of db/db
mice for both substrates. However, these tendencies were not
present in the relative OCR levels (Figures 2(c) and 2(d)),
suggesting little or no changes in cerebral mitochondrial utili-
zation of glutamate and glutamine in the db/db mouse.
3.2. Amino Acid Amounts of Isolated Cerebral Cortical and
Hippocampal Slices. The content of amino acids of cerebral
cortical and hippocampal slices from control and db/db mice
incubated in media containing [U-13C]glutamate or
[U-13C]glutamine is presented in Figure 3. No signiﬁcant
changes were observed in amino acid amounts of cerebral
cortical and hippocampal slices incubated in media contain-
ing [U-13C]glutamate (Figures 3(a) and 3(b)). A tendency
towards lower glutamate levels was observed in the
TCA
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Figure 1: Cartoon illustrating 13C labeling patterns from
[U-13C]glutamate and [U-13C]glutamine metabolism. Glutamate
M+5 can be converted into glutamine M+5 or GABA M+4
through glutamine synthetase (GS) or glutamate decarboxylase
(GAD) activity, respectively. Glutamine M+5 can likewise be
converted into glutamate M+5 through the action of phosphate-
activated glutaminase (PAG). Additionally, glutamate M+5 can be
converted into α-ketoglutarate M+5 by activity of either glutamate
dehydrogenase (GDH) or aspartate aminotransferase (AAT) and
be introduced into the TCA cycle. α-Ketoglutarate M+5 can be
metabolized in the TCA cycle, giving rise to 13C labeling in all
TCA cycle intermediates. Aspartate is in close equilibrium with
oxaloacetate trough AAT, giving rise to aspartate M+4 labeling.
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hippocampal slices of db/db mice (p = 0 12). Likewise, no
signiﬁcant changes in amino acid amounts were observed
for cerebral cortical and hippocampal slices of control and
db/db mice incubated in media containing [U-13C]glutamine
(Figures 3(c) and 3(d)). In addition, no signiﬁcant changes in
lactate amounts released to the media during the incubations
were observed (data not shown).
3.3. Metabolism of [U-13C]Glutamate in Acute Brain Slices.
Even though no changes in mitochondrial oxidation of gluta-
mate and glutamine were found in the db/db mouse, more
subtle regional changes could be present. To detect such
changes, acutely isolated cerebral cortical and hippocampal
slices were incubated in media containing [U-13C]glutamate
or [U-13C]glutamine, and isotopic enrichment was assessed
in tissue extracts by GC-MS analysis. The expected labeling
pattern of [U-13C]glutamate metabolism is depicted in
Figure 1. The 13C enrichment of amino acids and TCA cycle
intermediates from [U-13C]glutamate metabolism in cerebral
cortical and hippocampal slices from control and db/db mice
is presented in Figure 4. No apparent changes were observed
in 13C labeling from [U-13C]glutamate metabolism of
cerebral cortical slices from control and db/db mice
(Figure 4(a)). In contrast, 13C enrichment of several metabo-
lites was lower in hippocampal slices of db/db mice when
compared to controls (Figure 4(b)). Labeling of glutamate
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Figure 2: Mitochondrial oxygen consumption rates (OCRs) of isolated brain mitochondria from control and db/db mice. Absolute (a and b)
and relative (c and d) oxygen consumption rates of the brain mitochondria from control and db/db mice, with glutamate (a and c) and
glutamine (b and d), both in the presence of malate, as substrates. Arrows (in a and b) indicate the speciﬁc time points of compound
addition. ADP stimulates coupled respiration, oligomycin A inhibits the ATP synthase, FCCP induces uncoupled respiration, and
antimycin A inhibits complex III of the electron transport chain. Baseline is not shown. Results are presented as means± SEM, n = 4–7,
Student’s t-test, p < 0 05.
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M+5 was signiﬁcantly reduced (8%, p = 0 044). Additionally,
enrichment in glutamine M+5 and GABA M+4 was signiﬁ-
cantly decreased (10%, p = 0 048 and 19%, p = 0 0087, resp.)
in hippocampal slices of db/db mice compared to controls.
Since glutamate M+5 is the direct precursor of glutamine
M+5 and GABA M+4, the reduced labeling of the latter
two is likely a reﬂection of the decreased glutamate M+5
labeling. Furthermore, signiﬁcant decreases in citrate M+4
(13%, p = 0 045) and aspartate M+4 (9%, p = 0 037) were
observed from [U-13C]glutamate metabolism in the hippo-
campus of db/db mice. These results suggest an impaired
metabolism of glutamate, which could be linked to reduced
uptake of glutamate in hippocampal slices of db/db mice.
3.4. Metabolism of [U-13C]Glutamine in Acute Brain Slices.
The anticipated labeling pattern from metabolism of
[U-13C]glutamine is illustrated in Figure 1. 13C labeling of
amino acids and TCA cycle intermediates from [U-13C]glu-
tamine metabolism in cerebral cortical and hippocampal
slices from control and db/db mice are presented in
Figure 5. No signiﬁcant diﬀerences in 13C labeling were
observed in extracts of cerebral cortical slices of control and
db/db mice. However, as seen for the incubations with
[U-13C]glutamate, several diﬀerences were found in extracts
of hippocampal slices of db/db mice incubated with
[U-13C]glutamine. No signiﬁcant changes were observed in
glutamine M+5 or glutamate M+5, suggesting unaltered
glutamine uptake and PAG activity. However, labeling of
GABA M+4 was signiﬁcantly decreased (10%, p = 0 045) in
db/db mice compared to controls. Furthermore, labeling of
citrate M+4 and aspartate M+4 was signiﬁcantly reduced
(10%, p = 0 027 and 11%, p = 0 034, resp.) in hippocampal
slices of db/db mice. These results point towards hampered
metabolism of glutamine, downstream of glutamate, in the
hippocampus of db/db mice.
3.5. Expression Levels of Enzymes in the Metabolism of
Glutamate and Glutamine. The observed changes in 13C label-
ing from metabolism of [U-13C]glutamate and [U-13C]gluta-
mine could be due to altered expression of enzymes involved
in glutamate and glutamine turnover illustrated in Figure 1.
However, no changes were observed in the expressions of
GDH, AAT, GAD, PAG, or GS in cerebral cortical and
hippocampal homogenate of db/db and control mice (see
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Figure 3: Amino acid amounts in extracts of cerebral cortical and hippocampal slices of control and db/db mice. Amino acid amounts of
cerebral cortical (a and c) and hippocampal (b and d) slices of control and db/db mice incubated in media containing either
[U-13C]glutamate (a and b) or [U-13C]glutamine (c and d). Results are presented as means± SEM, n = 8–11, Student’s t-test, p < 0 05.
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Supplementary Figure 1 available online at https://doi.org/
10.1155/2017/2107084).
4. Discussion
In this study, we show that the mitochondrial capacity for oxi-
dative metabolism of glutamate and glutamine in the db/db
brain is maintained. However, hippocampal slices of db/db
mice exhibited hampered metabolism of glutamate and
glutamine, observed as decreased 13C labeling of several key
amino acids and TCA cycle intermediates. These results sug-
gest that both glutamate uptake and glutamine metabolism
are disturbed in the hippocampus of db/db mice, potentially
aﬀecting the homeostasis of the glutamate/glutamine cycle.
4.1. Cerebral Mitochondrial Function in Type 2 Diabetes. In
the present study, we show no signiﬁcant changes in oxygen
consumption of brain mitochondria from db/db mice when
provided with glutamate and glutamine, suggesting little or
no change in cerebral mitochondrial oxidation of these sub-
strates. Other studies have found impaired cerebral mito-
chondrial function in the brain of the db/db mouse, mainly
manifested as decreased expression or activity of the individ-
ual electron transport chain complexes in both the cerebral
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Figure 4: 13C labeling from [U-13C]glutamate metabolism of cerebral cortical and hippocampal slices of control and db/db mice. TCA cycle
intermediates and amino acids labeled from [U-13C]glutamate metabolism during incubations of cerebral cortical (a) and hippocampal (b)
slices of control and db/db mice. Results are presented as means± SEM, n = 8–11, Student’s t-test, ∗p < 0 05.
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Figure 5: 13C labeling from [U-13C]glutamine metabolism of cerebral cortical and hippocampal slices of control and db/db mice. TCA cycle
intermediates and amino acids labeled from [U-13C]glutamine metabolism during incubations of cerebral cortical (a) and hippocampal
(b) slices of control and db/db mice. Results are presented as means± SEM, n = 11, Student’s t-test, ∗p < 0 05.
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cortex and hippocampus [22, 23]. Huang et al. have recently
shown an age-related decline of complex I activity in the hip-
pocampus of db/db mice [23]. Other studies have, likewise,
found reduced hippocampal gene and protein expression
related to mitochondrial energetics in db/db mice [24, 25],
all suggesting that the mitochondria of the hippocampus
are aﬀected by T2DM. However, oxygen consumption, being
a measure of TCA cycle metabolism, electron transport,
and oxidative phosphorylation, does not suggest any func-
tional alterations in oxidative metabolism of glutamate and
glutamine in the db/db brain. We have recently shown, using
the same experimental setup, an augmented ADP-stimulated
respiration from isolated whole-brain mitochondria of db/db
mice when given pyruvate and malate as substrates [16]. This
could suggest mitochondrial compensatory mechanisms at
the level of oxidative phosphorylation in the db/db brain.
The enhanced mitochondrial function might try to counter-
balance the observed cerebral hypometabolism of glucose in
db/db mice [16]. Our previous observations are in line with
the results presented in this study, showing that mitochon-
drial oxidative function in the db/db brain is maintained.
However, it should be noted that the mitochondrial prepara-
tion used in this study, as done previously, was obtained from
whole-brain homogenate, meaning that potential regional
diﬀerences in mitochondrial function might be masked.
4.2. Glutamate/Glutamine Cycling in the Diabetic Brain.
Homeostasis of the glutamate/glutamine cycle is important
for normal brain function and has been shown to be altered
in T2DM animal models [26, 27]. Impairments of glutamate
or glutamine uptake could be reﬂected as quantitative
changes of these amino acids from extracts of the incubated
brain slices. We have previously found that the amounts of
the amino acids: aspartate, glutamate, glutamine, serine, ala-
nine, and GABA, were unaltered in extracts of both cerebral
cortical and hippocampal slices of db/db mice incubated in
media containing glucose as substrate [16]. This observation
is in accordance with previous ﬁndings by Makar et al. [28].
However, a recent study found signiﬁcant increased levels
of glutamate and decreased levels of glutamine in the hippo-
campus of 17-week-old db/db mice assessed by 1H-NMR
[26]. This study also reported qualitative changes in GS and
PAG expression using immunohistochemistry, coinciding
with the altered levels of glutamate and glutamine [26]. Our
results obtained from acutely isolated brain slices do not
support such changes in enzyme expression. From the
metabolismof [U-13C]glutamate, theenrichmentof glutamate
M+5 and glutamine M+5 was decreased to similar extents
(8% and 10%, resp.) in hippocampal slices of db/db mice,
suggesting intact GS activity. Likewise, from the metabolism
of [U-13C]glutamine, labeling of glutamate M+5 synthesized
by activity of PAG from glutamine M+5 was unaltered like its
precursor in hippocampal slices of db/db mice. These
observations are additionally supported by Western blot
analyses, ﬁnding no alterations in GS or PAG expression in
the cerebral cortex and hippocampus of db/db mice.
In the present study, we ﬁnd that GABA M+4 labeling is
decreased from both [U-13C]glutamate and [U-13C]glutamine
metabolism in hippocampal slices of db/db mice. It has
recently been suggested that the db/db mouse exhibits a
reduced hippocampal expression of GAD [26]. Astrocyte-
derived glutamine is the main precursor for neuronal GABA
synthesis, and the signiﬁcance of this has been established in
our current incubation setup [29]. The decreased enrichment
in GABA M+4 could be explained by an impaired transfer of
astrocytic glutamine to neurons. However, since GABA M+4
enrichment was reduced from the metabolism of both
[U-13C]glutamate and [U-13C]glutamine, this points towards
speciﬁc alterations in GAD functionality. The expressions of
both isoforms of GAD (GAD65 and GAD67) were found not
to be diﬀerent in hippocampal homogenate of db/dbmice. This
indicates decreased enzyme activity andnot protein expression.
We observed a reduced enrichment of glutamate M+5
and a tendency towards lower glutamate amounts, from
incubations of hippocampal slices in media containing
[U-13C]glutamate, pointing towards decreased hippocampal
glutamate uptake in db/db mice. It has been shown that the
rate of astrocytic oxidation of glutamate rises with increasing
exogenous glutamate concentrations [12]. In the present
incubation study, 0.5mM exogenous [U-13C]glutamate was
applied. This concentration is relatively high, testing both
glutamate uptake and metabolism for an extended period of
time. Glutamate uptake is energetically expensive, as it is
coupled to cotransport Na+, requiring high activity of the
Na+/K+-ATPase to maintain ionic homeostasis [8]. Interest-
ingly, it has been shown that db/db mice exhibits a reduced
activity of the Na+/K+-ATPase in whole-brain homogenate,
which could be linked to a reduced glutamate uptake [28].
Reduced uptake of glutamate has previously been described
in the diabetic brain, which is in line with our results suggest-
ing impairments in this important part of the glutamate/glu-
tamine cycle in the hippocampus [30, 31]. Interestingly, it has
been suggested that the Na+/K+-ATPase is mainly fueled by
glycolytically derived ATP [32]. This might explain the
decreased glutamate uptake, since we previously have shown
hypometabolism of glucose in the brain of db/db mice [16].
The reduced labeling observed from incubations with
[U-13C]glutamine could arise from reduced neuronal TCA
cycle activity, as recently shown in a mouse model of early
AD [19]. If the TCA cycle activity is decreased, the need for
introduction of α-ketoglutarate derived from glutamine
through glutamate likewise falls, leading to reduced 13C label-
ing. However, since only reduced labeling is observed in
citrate M+4 and no other TCA cycle intermediate, this is
not a likely explanation. In addition, our results indicate that
glutamine uptake and conversion into glutamate are unaf-
fected. The main enzymes converting glutamate into α-keto-
glutarate are AAT and GDH as outlined in Figure 1 [7]. One
study has reported a decreased expression of AAT in the
hippocampus of db/db mice [24]. This observation is in line
with our results, since aspartate M+4 labeling was reduced
from the metabolism of both [U-13C]glutamate and [U-13C]-
glutamine, suggesting reduced activity of AAT in the
hippocampus of db/db mice. The reduced labeling in citrate
M+4, likewise observed for both [U-13C]glutamate and
[U-13C]glutamine metabolism, is also in line with hampered
AAT activity. Since aspartate is in fast equilibrium with
oxaloacetate, decreased AAT activity would lead to reduced
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labeling of oxaloacetate M+4, which is reﬂected in citrate
M+4. We were not able to detect any changes in either
AAT or GDH expression in cerebral cortical or hippocampal
homogenate of db/db mice.
4.3. Hippocampal Impairments in Type 2 Diabetes. We have
recently shown that glucose hypometabolism is present in
both the cerebral cortex and hippocampus of the db/dbmouse,
being more prominent in the cerebral cortex [16]. In the
current study, changes in glutamate and glutamine metabo-
lism were exclusively present in the hippocampus. It has been
suggested that the hippocampus is particularly vulnerable to
metabolic alterations in T2DM and this has been associated
with memory deﬁcits [4, 6]. Indeed, several studies have
determined that the db/db mouse exhibits cognitive impair-
ments [18, 33, 34]. In addition, several speciﬁc mitochondrial
changes have been found in the hippocampus of db/db mice
[23–25]. Alterations in electrophysiological functions, speciﬁ-
cally decreased hippocampal long-term potentiation and
depression, important for memory and learning, have been
shown in the db/db mouse [23, 33, 34]. All of these speciﬁc
impairments in the hippocampus of the db/db mouse are in
line with our results of hippocampal changes in the gluta-
mate/glutamine cycle, not being present in the cerebral cortex.
Our results are intriguing in the context of the accelerated
development of AD in relation to T2DM, and the speciﬁc hip-
pocampal changes in glutamate and glutamine metabolism
could be important factors of the underlying pathology.
5. Conclusions
We provide evidence that mitochondrial oxidation of gluta-
mate and glutamine in the brain of the db/db mouse is
unaltered. However, hippocampal slices of db/db mice exhib-
ited reduced glutamate uptake and metabolism of glutamine,
changes that were not observed in the cerebral cortex. Our
ﬁndings suggest speciﬁc impairments in hippocampal GAD
and AAT activities, likely aﬀecting homeostasis of the gluta-
mate/glutamine cycle, which could be linked to cognitive
deﬁcits in db/db mice.
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